Akeso
Pharmaceuticals, Cayenne CRK Ct, 中山, , 92127, California, 15306, United States, 1001-5000 Employees
Who is AKESO
Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medic...
Read More
-
Headquarters: 15306 Cayenne CRK Ct, 中山, California, 92127, United States
-
Date Founded: 2012
-
Employees: 1001-5000
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Akeso Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Akeso
Answer: Akeso's headquarters are located at Cayenne CRK Ct, 中山, , 92127, California, 15306, United States
Answer: Akeso's official website is https://akesobio.com
Answer: Akeso's revenue is $10 Million to $25 Million
Answer: Akeso's SIC: 2834
Answer: Akeso's NAICS: 325412
Answer: Akeso has 1001-5000 employees
Answer: Akeso is in Pharmaceuticals
Answer: Akeso contact info: Phone number: Website: https://akesobio.com
Answer: Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month